CytoDyn Inc. Quarterly Research and Development Expense in USD from Q3 2010 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary: CytoDyn Inc. quarterly/annual Research and Development Expense history and growth rate from Q3 2010 to Q2 2024.
CytoDyn Inc. Research and Development Expense for the quarter ending May 31, 2024 was $3.6M, a 267% increase year-over-year.
CytoDyn Inc. Research and Development Expense for the twelve months ending May 31, 2024 was $7.24M, a 175% increase year-over-year.
CytoDyn Inc. annual Research and Development Expense for 2023 was $7.24M, a 175% increase from 2022.
CytoDyn Inc. annual Research and Development Expense for 2022 was $2.63M, a 90.3% decline from 2021.
CytoDyn Inc. annual Research and Development Expense for 2021 was $27M, a 49.4% decline from 2020.

Research and Development Expense, Trailing 12 Months (USD)

Research and Development Expense, Quarterly (USD)

Research and Development Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$7.24M	$3.6M	+$2.62M	+267%	Mar 1, 2024	May 31, 2024	10-K	2024-08-15
Q1 2024	$4.62M	$650K	-$288K	-30.7%	Dec 1, 2023	Feb 29, 2024	10-Q	2024-04-15
Q4 2023	$4.91M	$1.08M	+$942K	+688%	Sep 1, 2023	Nov 30, 2023	10-Q	2024-01-16
Q3 2023	$3.97M	$1.91M	+$1.34M	+232%	Jun 1, 2023	Aug 31, 2023	10-Q	2023-10-23
Q2 2023	$2.63M	$981K	-$3.03M	-75.5%	Mar 1, 2023	May 31, 2023	10-K	2024-08-15
Q1 2023	$5.66M	$938K	-$2.63M	-73.7%	Dec 1, 2022	Feb 28, 2023	10-Q	2024-04-15
Q4 2022	$8.29M	$137K	-$7.31M	-98.2%	Sep 1, 2022	Nov 30, 2022	10-Q	2024-01-16
Q3 2022	$15.6M	$576K	-$11.4M	-95.2%	Jun 1, 2022	Aug 31, 2022	10-Q	2023-10-23
Q2 2022	$27M	$4.01M	-$5.44M	-57.6%	Mar 1, 2022	May 31, 2022	10-K	2023-09-14
Q1 2022	$32.5M	$3.57M	-$8.75M	-71%	Dec 1, 2021	Feb 28, 2022	10-Q	2023-04-10
Q4 2021	$41.2M	$7.45M	-$9M	-54.7%	Sep 1, 2021	Nov 30, 2021	10-Q	2023-01-09
Q3 2021	$50.2M	$12M	-$3.17M	-20.9%	Jun 1, 2021	Aug 31, 2021	10-Q/A	2022-10-13
Q2 2021	$53.4M	$9.45M	-$10.5M	-52.6%	Mar 1, 2021	May 31, 2021	10-K	2022-08-15
Q1 2021	$63.9M	$12.3M	-$2.79M	-18.4%	Dec 1, 2020	Feb 28, 2021	10-Q	2022-04-11
Q4 2020	$66.7M	$16.4M	+$7.92M	+92.9%	Sep 1, 2020	Nov 30, 2020	10-Q	2022-01-10
Q3 2020	$58.8M	$15.2M	+$6.13M	+67.7%	Jun 1, 2020	Aug 31, 2020	10-Q	2021-10-12
Q2 2020	$52.6M	$19.9M	+$10.8M	+117%	Mar 1, 2020	May 31, 2020	10-K	2022-08-15
Q1 2020	$41.9M	$15.1M	+$6.09M	+67.5%	Dec 1, 2019	Feb 29, 2020	10-Q	2021-04-14
Q4 2019	$35.8M	$8.53M	-$4.34M	-33.7%	Sep 1, 2019	Nov 30, 2019	10-Q	2021-01-08
Q3 2019	$40.1M	$9.06M	-$2.35M	-20.6%	Jun 1, 2019	Aug 31, 2019	10-Q	2020-10-09
Q2 2019	$42.5M	$9.2M	+$274K	+3.08%	Mar 1, 2019	May 31, 2019	10-K	2021-07-30
Q1 2019	$42.2M	$9.02M	-$3.05M	-25.3%	Dec 1, 2018	Feb 28, 2019	10-Q	2020-04-09
Q4 2018	$45.3M	$12.9M	+$3.79M	+41.8%	Sep 1, 2018	Nov 30, 2018	10-Q	2020-01-09
Q3 2018	$41.5M	$11.4M	+$3.26M	+39.9%	Jun 1, 2018	Aug 31, 2018	10-Q	2019-10-08
Q2 2018	$38.2M	$8.92M	+$3.32M	+59.2%	Mar 1, 2018	May 31, 2018	10-K	2020-08-14
Q1 2018	$34.9M	$12.1M	+$5.54M	+84.8%	Dec 1, 2017	Feb 28, 2018	10-Q	2019-04-09
Q4 2017	$29.4M	$9.08M	+$4.69M	+107%	Sep 1, 2017	Nov 30, 2017	10-Q	2019-01-09
Q3 2017	$24.7M	$8.15M	+$4.46M	+121%	Jun 1, 2017	Aug 31, 2017	10-Q	2018-10-09
Q2 2017	$20.2M	$5.6M	+$1.58M	+39.4%	Mar 1, 2017	May 31, 2017	10-K	2019-08-14
Q1 2017	$18.6M	$6.53M	+$3.79M	+138%	Dec 1, 2016	Feb 28, 2017	10-Q	2018-04-09
Q4 2016	$14.8M	$4.38M	+$2.72M	+164%	Sep 1, 2016	Nov 30, 2016	10-Q	2018-01-08
Q3 2016	$12.1M	$3.69M	-$1.62M	-30.6%	Jun 1, 2016	Aug 31, 2016	10-Q	2017-10-10
Q2 2016	$13.7M	$4.02M	-$4.72M	-54%	Mar 1, 2016	May 31, 2016	10-K	2018-07-27
Q1 2016	$18.5M	$2.74M	+$477K	+21.1%	Dec 1, 2015	Feb 29, 2016	10-Q	2017-04-13
Q4 2015	$18M	$1.66M	-$426K	-20.4%	Sep 1, 2015	Nov 30, 2015	10-Q	2017-01-13
Q3 2015	$18.4M	$5.31M	+$3.25M	+157%	Jun 1, 2015	Aug 31, 2015	10-Q	2016-10-12
Q2 2015	$15.2M	$8.74M	+$7.12M	+438%	Mar 1, 2015	May 31, 2015	10-K	2016-07-19
Q1 2015	$8.04M	$2.26M	+$608K	+36.7%	Dec 1, 2014	Feb 28, 2015	10-Q	2016-04-13
Q4 2014	$7.43M	$2.09M	+$1.54M	+285%	Sep 1, 2014	Nov 30, 2014	10-Q	2016-01-11
Q3 2014	$5.89M	$2.06M	+$1.9M	+1201%	Jun 1, 2014	Aug 31, 2014	10-Q	2015-10-09
Q2 2014	$3.98M	$1.62M	+$1.26M	+345%	Mar 1, 2014	May 31, 2014	10-K	2015-07-10
Q1 2014	$2.72M	$1.66M	+$1.62M	+4862%	Dec 1, 2013	Feb 28, 2014	10-Q	2015-04-10
Q4 2013	$1.1M	$543K	+$382K	+237%	Sep 1, 2013	Nov 30, 2013	10-Q	2015-01-12
Q3 2013	$718K	$159K	+$98.1K	+162%	Jun 1, 2013	Aug 31, 2013	10-Q	2014-10-10
Q2 2013	$620K	$365K	+$249K	+215%	Mar 1, 2013	May 31, 2013	10-K	2014-07-10
Q1 2013	$371K	$33.4K	-$38.1K	-53.3%	Dec 1, 2012	Feb 28, 2013	10-Q	2014-04-11
Q4 2012	$409K	$161K	-$8.18K	-4.84%	Sep 1, 2012	Nov 30, 2012	10-Q	2014-01-13
Q3 2012	$417K	$60.5K	-$113K	-65.1%	Jun 1, 2012	Aug 31, 2012	10-Q	2013-10-15
Q2 2012	$530K	$116K	+$116K		Mar 1, 2012	May 31, 2012	10-K	2013-08-29
Q1 2012	$414K	$71.5K	-$156K	-68.6%	Dec 1, 2011	Feb 29, 2012	10-Q	2013-04-12
Q4 2011	$570K	$169K	-$56.8K	-25.1%	Sep 1, 2011	Nov 30, 2011	10-Q	2013-01-14
Q3 2011	$627K	$173K	+$146K	+537%	Jun 1, 2011	Aug 31, 2011	10-Q/A	2012-11-08
Q2 2011	$481K	$0			Mar 1, 2011	May 31, 2011	10-K	2012-08-22
Q1 2011		$228K			Dec 1, 2010	Feb 28, 2011	10-Q	2012-04-16
Q4 2010		$226K			Sep 1, 2010	Nov 30, 2010	10-Q	2012-01-17
Q3 2010		$27.3K			Jun 1, 2010	Aug 31, 2010	10-Q/A	2011-11-30

* An asterisk sign (*) next to the value indicates that the value is likely invalid.